Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

It's a buyer's market for type 2 diabetes drugs, and you can thank FDA for that. At least, that is the sentiment of business development executives from Big Pharma. Transaction data in 2008 back up that view.

If you think this is a bad time to try to get a loan, try selling a type 2 diabetes research project to a Big Pharma company.

Diabetes, simultaneously one of the largest yet most under-treated prescription drug markets in the world, is suddenly out-of-favor with Big...

More from Archive

More from Pink Sheet